Ferrous Sulfate Dosing Recommendations for Iron‑Deficiency Anemia
Initial Dosing Strategy
- The recommended starting dose is 50–100 mg elemental iron once daily (e.g., one 200 mg ferrous‑sulfate tablet providing 65 mg elemental iron) for adults with iron‑deficiency anemia. 1
- The 2024 American Gastroenterological Association (AGA) guideline and the 2021 British Society of Gastroenterology (BSG) guideline give a strong recommendation for once‑daily dosing rather than multiple daily doses. 2
Rationale for Once‑Daily Dosing
- A single oral dose of ≈60 mg elemental iron raises hepcidin levels, which remain elevated for up to 48 hours and block further iron absorption; therefore, additional doses within this window provide little extra absorption. Strong evidence supporting this mechanism. 2
- Once‑daily dosing does not improve total iron absorption compared with twice‑daily dosing but significantly increases gastrointestinal adverse events. 2
- Pharmacokinetic studies show that 60 mg elemental iron once daily yields overall absorption comparable to 60 mg twice daily. 3
Timing and Administration
- Take the tablet on an empty stomach (≥1 hour before or 2 hours after food) to achieve optimal absorption. 2
- If gastrointestinal intolerance occurs, the tablet may be taken with meals, acknowledging a modest reduction in absorption. 2
- Co‑administration of 80–500 mg vitamin C (ascorbic acid) enhances non‑heme iron absorption. 2
- Avoid tea or coffee within one hour of the dose because polyphenols markedly inhibit iron uptake. 2
Alternative Dosing for Intolerance
- When the standard once‑daily dose is poorly tolerated, switch to alternate‑day dosing (one tablet every other day). 1
- Alternate‑day regimens delivering 100–200 mg elemental iron provide higher fractional iron absorption than daily dosing. 3
- This strategy reduces gastrointestinal side effects (relative risk ≈ 0.56) while maintaining overall efficacy. Moderate‑quality evidence. 4
- Hemoglobin rise may be slower initially, but final hemoglobin increments are comparable after the same cumulative iron dose. 1
Monitoring and Treatment Duration
- Check hemoglobin after 2 weeks of therapy; an increase of ≥1 g/dL indicates an effective response. High sensitivity (≈90 %) for predicting treatment failure if this rise is absent. 1
- If the expected rise is not observed, consider escalation to intravenous iron. 2
- After hemoglobin normalizes, continue oral iron for ≈3 months to replenish iron stores. 1
- Monitor hemoglobin every 4 weeks until normalization. 4
- Following completion of therapy, re‑check a complete blood count every 6 months (initially) to detect recurrence. 1
Indications to Switch to Intravenous Iron
- Intolerance to oral iron despite dose reduction (e.g., alternate‑day regimen). 5
- No hemoglobin increase after 2 weeks of adherent oral therapy. 2
- Conditions that impair absorption (post‑bariatric surgery, active inflammatory bowel disease). 2
- Iron losses exceeding the capacity of oral absorption (e.g., ongoing heavy bleeding). 2
- Severe symptomatic anemia requiring rapid correction. Strong recommendation in guideline statements. 4
Common Pitfalls to Avoid
- Do not prescribe twice‑ or three‑times‑daily dosing as first‑line; it raises side‑effects without improving absorption. 2
- Do not use modified‑release iron formulations; they are less effective for oral repletion. 1
- Do not continue ineffective oral therapy indefinitely; reassess at 2 weeks and switch to IV iron if no response. 2
- Do not stop therapy when hemoglobin normalizes; continue for an additional 3 months to restore stores. 1
Side‑Effect Profile
- Overall gastrointestinal adverse events occur in 12–31 % of patients receiving oral ferrous sulfate. 2
- Constipation: ≈12 %
- Diarrhea: ≈8 %
- Nausea: ≈11 %
- These side effects are dose‑dependent and can be mitigated by alternate‑day dosing. 4